1. Pink Sheet
  2. >>R&D
  3. >>Clinical Trials

Clinical Trials: Building Quality At The Start Means Reducing Errors That Matter

 
• By Sue Sutter

Despite encouragement from regulators, quality-by-design and risk-based monitoring approaches for clinical trials have not been fully adopted. Experts say careful, cross-disciplinary thinking is needed in the study design phase, along with adoption of the quality mentality seen on the manufacturing side.  

Young plant
Quality should be built into clinical trials from the start. • Source: Shutterstock (Shutterstock)

Building quality into clinical trials up-front requires careful, cross-disciplinary thinking during the design phase about the most important risks to a study and adoption of the type of quality mindset that guides pharmaceutical manufacturing, experts said.

Key Takeaways

  • US and international regulators are encouraging incorporation of quality-by-design and risk-based monitoring approaches into clinical trials, but a risk-averse industry has been slow to embrace them outside the COVID-19 pandemic.

Regulators, industry representatives, clinical trial experts and patient advocacy groups discussed successes and challenges in integrating quality-by-design (QbD) and risk-based...

More from Clinical Trials

HHS Wants Employees (And Public?) To Report Diversity, Equity And Inclusion Discrimination

 
• By Sue Sutter

A survey asks FDA staff to disclose whether DEI policies caused discrimination or resulted in disciplinary action against career employees over the past five years, but uses a web form that the general public also can access.

Bayesian Statistics In EU Clinical Trials: EMA Discusses Balancing Efficiency With Rigor

 
• By Eliza Slawther

Bayesian statistics could help clinical trial sponsors to include external information in their analyses, but concerns around bias and incorrect conclusions remain, the European Medicines Agency said.

Adaptive Clinical Trials Require ‘Clear And Compelling Justification’

 
• By Vibha Sharma

A draft international guideline on using adaptive trial designs says sponsors should provide a clear rationale for using such designs to address the potential ‘tension’ between the confirmatory nature of late-stage trials and the flexibility introduced by mid-trial adaptations.

Denmark Sets New EU Benchmark With 14-Day Clinical Trial Review Timeline

 
• By Vibha Sharma

Denmark is shaking up clinical trial timelines with a new process for reviewing applications for early-phase mono-national trials that is twice as fast as the standard timelines in the EU and the UK.

More from R&D

Adaptive Clinical Trials Require ‘Clear And Compelling Justification’

 
• By Vibha Sharma

A draft international guideline on using adaptive trial designs says sponsors should provide a clear rationale for using such designs to address the potential ‘tension’ between the confirmatory nature of late-stage trials and the flexibility introduced by mid-trial adaptations.

Denmark Sets New EU Benchmark With 14-Day Clinical Trial Review Timeline

 
• By Vibha Sharma

Denmark is shaking up clinical trial timelines with a new process for reviewing applications for early-phase mono-national trials that is twice as fast as the standard timelines in the EU and the UK.

Clinical Trial Diversity Action Plan Guidance Must Return To US FDA Website, Court Says

 
• By Sue Sutter

HHS and its agencies violated the law by swiftly implementing “sweeping and poorly thought-through directives that ordered the bulk removal of healthcare resources,” including FDA draft guidances on diversity action plans and sex differences in clinical trials, a federal court said.